{"protocolSection": {"identificationModule": {"nctId": "NCT01508936", "orgStudyIdInfo": {"id": "C38072/3084"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma", "officialTitle": "A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma"}, "statusModule": {"statusVerifiedDate": "2016-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02"}, "primaryCompletionDateStruct": {"date": "2013-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-01-03", "studyFirstSubmitQcDate": "2012-01-10", "studyFirstPostDateStruct": {"date": "2012-01-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-23", "resultsFirstSubmitQcDate": "2016-05-26", "resultsFirstPostDateStruct": {"date": "2016-06-27", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-05-08", "dispFirstSubmitQcDate": "2014-05-08", "dispFirstPostDateStruct": {"date": "2014-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-05-26", "lastUpdatePostDateStruct": {"date": "2016-06-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1)."}, "conditionsModule": {"conditions": ["Eosinophilic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 511, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses.", "interventionNames": ["Drug: Placebo"]}, {"label": "Reslizumab 3.0 mg/kg", "type": "EXPERIMENTAL", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.", "interventionNames": ["Drug: Reslizumab"]}], "interventions": [{"type": "DRUG", "name": "Reslizumab", "description": "Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).", "armGroupLabels": ["Reslizumab 3.0 mg/kg"], "otherNames": ["Cinquil", "humanized monoclonal antibody", "CEP-38072"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry.\n\nData represent the slope estimate of change from baseline in FEV1 (measured in liters) at Week 16 versus baseline eosinophil count (measured in 10\\^9/liter) by treatment group.", "timeFrame": "Baseline (Day 1), Week 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.\n\nDuring study (Weeks 4, 8, 12 and 16) average value was calculated using a mixed effects model for repeated measures (MMRM) with treatment (reslizumab or placebo), blood eosinophil count at baseline, and the interaction of treatment and eosinophil count as a random effect.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ACQ score was measured using the ACQ-7. Six questions are-self assessments; the seventh item is the result of the patient's % predicted FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A score of 0 indicates good asthma control; higher scores indicate increasingly poorer asthma control. Negative change from baseline scores indicate improvement in asthma control.\n\nDuring study (Weeks 4, 8, 12 and 16) average value was calculated from mixed model repeated measures (MMRM) with treatment, visit, treatment by visit interaction, history of asthma exacerbation in the previous year, height, baseline value, and sex as fixed factors, and patient as a random effect.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopulation", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry.\n\nAs with the primary outcome, data represent the slope estimate of change from baseline in FEV1 (measured in liters) at Week 16 versus baseline eosinophil count (measured in 10\\^9/liter) by treatment group. However the FEV1 subpopulation includes participants with more impaired lung function (% predicted FEV1 \\<85% at baseline).", "timeFrame": "Baseline (Day 1), Week 16"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16"}, {"measure": "Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16 and Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva. Positive change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 4, 8, 12, and 16", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters. FV was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16"}, {"measure": "Change From Baseline in the Forced Expiratory Flow at 25% to 75% of the Forced Vital Capacity (FEF25%-75%) at Weeks 4, 8, 12, and 16", "description": "The FEF25%-75% is the forced expiratory flow at 25% to 75% of the forced vital capacity. FEF25%-75% was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16"}, {"measure": "Change From Baseline in Average Daily Use of Short-Acting Beta-Agonist Therapy (SABA) at Weeks 4, 8, 12, and 16", "description": "SABA are used for quick relief of asthma symptoms. The number of times SABA therapy was used was assessed using 3 day recall at scheduled visits. Participants were asked to recall whether SABAs were used within 3 days of the scheduled visit and, if so, how many puffs were used. Daily use was the average of those 3 days. Negative change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day -2 to 1), Weeks 4, 8, 12, and 16"}, {"measure": "Change From Baseline in Blood Eosinophil Counts at Weeks 4, 8, 12, 16, Follow-up (Week 28) and Endpoint", "description": "Blood eosinophil counts were measured using a standard complete blood count with differential blood test at each scheduled visit. Follow-up was performed approximately 12 weeks after the 16 week treatment period. Endpoint is the last post-baseline assessment.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16, Follow-up (Week 28)"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12 and 16", "description": "The ACQ score was measured using the ACQ-7. Six questions are self-assessments; the seventh item is the result of the patient's % predicted FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A score of 0 indicates good asthma control; higher scores indicate increasingly poorer asthma control. Negative change from baseline scores indicate improvement in asthma control.", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12 and 16"}, {"measure": "Participants With Treatment-Emergent Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "Day 1 to Week 28"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values during any of the lab tests conducted during the treatment period.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* Aspartate aminotransferase: \\>=3\\*upper limit of normal (ULN). Normal range is 10-43 U/L\n* Alanine aminotransferase: \\>=3\\*ULN. Normal range is 10-40 U/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*ULN. Normal range is 4-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* Creatinine phosphokinase: \\>5\\*ULN. Normal range is 24-207 U/L.\n* White blood cells: \\<=3.0 or \\>20 10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 L/L\n* Platelets: \\<=75 10\\^9/L\n* Absolute neutrophil count: \\<=1.0 10\\^9/L\n* Urinalysis: blood, glucose, ketones and total protein: \\>=2 unit increase from baseline", "timeFrame": "Week 4 to Week 16"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with potentially clinically significant (PCS) vital sign values during any of the treatment period exams.\n\nSignificance criteria\n\n* Heart rate - high: \\>100 and increase of \\>= 30 beats/minute (bpm)\n* Sitting systolic blood pressure - high: \\>160 and increase of \\>=30 mmHg\n* Sitting systolic blood pressure - low: \\<90 and decrease of \\>=30 mmHg\n* Sitting diastolic blood pressure - high: \\>100 and increase of \\>=12 mmHg\n* Sitting diastolic blood pressure - low: \\<50 and decrease of \\>=12 mmHg\n* Body temperature - high: \\>100.5\u00b0 Fahrenheit or 38.1\u00b0 Celsius and increase of \\>2\u00b0\n* Body temperature - low: \\<96.5\u00b0 Fahrenheit or \\<35.8\u00b0 Celsius", "timeFrame": "Week 4 to Week 28"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Electrocardiogram (ECG) Abnormalities", "description": "Counts represent the number of participants with potentially clinically significant ECG abnormalities as assessed by the investigator.", "timeFrame": "Week 16 or endpoint"}, {"measure": "Participants With a Positive Anti-Reslizumab Antibody Status During Study", "description": "Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion at screening, weeks 8 and 16 or early withdrawal. Serum samples from patients who were treated with reslizumab were analyzed for ADA by Teva (Teva Biopharmaceuticals USA, Rockville, MD) using a validated homogeneous solution-based bridging enzyme-linked immunosorbent assay (ELISA).\n\nEndpoint =week 16 or early withdrawal.\n\nCounts represent the total number of participants at each time point with a positive immunogenicity test, and not 'new' participants with a positive test. An overall status of positive includes participants who had a positive ADA at any time point.", "timeFrame": "Screening (Week -3), Weeks 8 and 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\nPatients are included in the study if all of the following criteria are met:\n\n* The patient is a man or woman, 18 through 65 years of age, with a diagnosis of asthma.\n* The patient has an ACQ score of at least 1.5.\n* At screening, the patient has airway reversibility of at least 12% to beta-agonist administration.\n* The patient is currently taking fluticasone at a dosage of at least 440 \u00b5g daily (or equivalent). Patients' baseline asthma therapy regimens (including but not limited to inhaled corticosteroids, leukotriene antagonists, 5-lipoxygenase inhibitors, cromolyn) must be stable for 30 days before screening and continue without dosage changes throughout study.\n* Female patients must be surgically sterile, 2 years postmenopausal, or must have a negative beta-human chorionic gonadotropin (\u00dfHCG) result for a pregnancy test at screening (serum) and baseline (urine).\n* Female patients of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include barrier method with spermicide, abstinence, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected).\n* Written informed consent is obtained.\n* The patient is in reasonable health (except for diagnosis of asthma) as judged by the investigator, and as determined by a medical history, medical examination, electrocardiogram (ECG) evaluation, serum chemistry, hematology, urinalysis, and serology.\n* The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and be willing to return to the clinic for the follow-up evaluation as specified in this protocol.\n\nExclusion Criteria:\n\nPatients are excluded from participating in this study if 1 or more of the following criteria are met:\n\n* The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, lung cancer). The patient has other pulmonary conditions with symptoms of asthma and blood eosinophilia (eg, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis).\n* The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.\n* The patient has known hypereosinophilic syndrome (HES).\n* The patient is a current smoker (ie, has smoked within the last 6 months prior to screening).\n* The patient has a history of use of systemic immunosuppressive or immunomodulating agents (anti-immunoglobulin E \\[anti-IgE\\] mAb, methotrexate, cyclosporin, interferon-\u03b1, anti-tumor necrosis factor mAb, or omalizumab) within 6 months prior to study entry (randomization).\n* The patient is currently using or has used systemic corticosteroids (includes use of oral corticosteroids) within 30 days prior to the screening visit.\n* The patient is expected to be poorly compliant with study drug administration, study procedures, or visits.\n* The patient has any aggravating factors that are inadequately controlled, and thus would aggravate asthma symptoms (eg, gastroesophageal reflux disease).\n* The patient has participated in any investigative drug or device study within 30 days prior to screening.\n* The patient has participated in any investigative biologics study within 90 days prior to screening.\n* The patient has previously received reslizumab or other anti-hIL-5 mAbs (eg, mepolizumab).\n* The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)\n* The patient has a current infection or disease that may preclude assessment of asthma.\n* The patient has a history of concurrent immunodeficiency (human immunodeficiency, acquired immunodeficiency syndrome, or congenital immunodeficiency).\n* The patient is suspected of current drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.\n* The patient has presence of or suspected parasitic infestation/infection.\n* Patients may not have received any live attenuated vaccine within the 12-week period before study entry.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Respiratory Clinical Research, M.D.", "affiliation": "Sponsor's Medical Expert", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site 861", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Investigational Site 842", "city": "Homewood", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.47177, "lon": -86.80082}}, {"facility": "Investigational Site 887", "city": "Jasper", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.83122, "lon": -87.27751}}, {"facility": "Investigational Site 809", "city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Investigational Site 892", "city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Investigational Site 846", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Investigational Site 828", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Investigational Site 900", "city": "Fresno", "state": "California", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Investigational Site 862", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Investigational Site 852", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site 909", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site 864", "city": "Newport Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Investigational Site 812", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Investigational Site 808", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Investigational Site 804", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Investigational Site 837", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Investigational Site 851", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site 832", "city": "Wheat Ridge", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Investigational Site 855", "city": "Jacksonville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Investigational Site 865", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Investigational Site 881", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Investigational Site 805", "city": "Albany", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Investigational Site 870", "city": "Stockbridge", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Investigational Site 816", "city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site 824", "city": "Shiloh", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 38.56144, "lon": -89.89732}}, {"facility": "Investigational Site 883", "city": "Evansville", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Investigational Site 878", "city": "Fort Wayne", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.1306, "lon": -85.12886}}, {"facility": "Investigational Site 820", "city": "Lenexa", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 38.95362, "lon": -94.73357}}, {"facility": "Investigational Site 873", "city": "Owensboro", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Investigational Site 801", "city": "Lafayette", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.22409, "lon": -92.01984}}, {"facility": "Investigational Site 877", "city": "Mandeville", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.35825, "lon": -90.06563}}, {"facility": "Investigational Site 875", "city": "White Marsh", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Investigational Site 871", "city": "Fall River", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Investigational Site 834", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Investigational Site 889", "city": "Troy", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.60559, "lon": -83.14993}}, {"facility": "Investigational Site 838", "city": "Rolla", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "Investigational Site 818", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site 841", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site 857", "city": "Albuquerque", "state": "New Mexico", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Investigational Site 819", "city": "Newburgh", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "Investigational Site 844", "city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site 845", "city": "Middleburg Heights", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Investigational Site 810", "city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Investigational Site 859", "city": "Ashland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.19458, "lon": -122.70948}}, {"facility": "Investigational Site 859", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Investigational Site 854", "city": "Jenkintown", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.09594, "lon": -75.12517}}, {"facility": "Investigational Site 843", "city": "Providence", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Investigational Site 802", "city": "Florence", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.19543, "lon": -79.76256}}, {"facility": "Investigational Site 814", "city": "Orangeburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "Investigational Site 821", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Investigational Site 829", "city": "Spartanburg", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Investigational Site 850", "city": "Knoxville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Investigational Site 803", "city": "Nashville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Investigational Site 880", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site 858", "city": "Dickinson", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.46079, "lon": -95.05132}}, {"facility": "Investigational Site 869", "city": "Live Oak", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "Investigational Site 879", "city": "Plano", "state": "Texas", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Investigational Site 847", "city": "Salt Lake City", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Investigational Site 876", "city": "West Jordan", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.60967, "lon": -111.9391}}, {"facility": "Investigational Site 840", "city": "Fairfax", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Investigational Site 836", "city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Investigational Site 867", "city": "Seattle", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Investigational Site 833", "city": "Spokane", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Investigational Site 904", "city": "Vancouver", "state": "Washington", "country": "United States", "geoPoint": {"lat": 45.63873, "lon": -122.66149}}, {"facility": "Investigational Site 806", "city": "Greenfield", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Investigational Site 823", "city": "LaCrosse", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.80136, "lon": -91.23958}}]}, "referencesModule": {"references": [{"pmid": "27018175", "type": "DERIVED", "citation": "Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016 Oct;150(4):799-810. doi: 10.1016/j.chest.2016.03.018. Epub 2016 Mar 25."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Randomization was stratified by occurrence of asthma exacerbation(s) during the previous year (yes or no). Within each stratum, patients were randomly assigned in a 4:1 ratio to receive treatment with reslizumab at 3.0 mg/kg or matching placebo.", "recruitmentDetails": "A total of 869 patients were screened for enrollment into this study. Of the 869 patients screened, 511 patients at 103 centers in the US met entry criteria and were considered to be eligible for enrollment into the study.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "FG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "102"}, {"groupId": "FG001", "numSubjects": "409"}]}, {"type": "Randomized, Not Analyzed", "achievements": [{"groupId": "FG000", "comment": "Participants from two centers were omitted from all analyses.", "numSubjects": "4"}, {"groupId": "FG001", "comment": "Participants from two centers were omitted from all analyses.", "numSubjects": "11"}]}, {"type": "Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "98"}, {"groupId": "FG001", "numSubjects": "398"}]}, {"type": "Randomized, Not Treated", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "395"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "395"}]}, {"type": "FEV1 Subpopulation Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "numSubjects": "346"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "330"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "79"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Data from 2 sites deemed invalid", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized, analyzed", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "BG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "398"}, {"groupId": "BG002", "value": "496"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.1", "spread": "13.38"}, {"groupId": "BG001", "value": "44.9", "spread": "12.00"}, {"groupId": "BG002", "value": "44.9", "spread": "12.27"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "261"}, {"groupId": "BG002", "value": "315"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "181"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "260"}, {"groupId": "BG002", "value": "333"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "134"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Non-Hispanic and Non-Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "354"}, {"groupId": "BG002", "value": "444"}]}]}, {"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "52"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.9", "spread": "20.68"}, {"groupId": "BG001", "value": "90.6", "spread": "23.92"}, {"groupId": "BG002", "value": "90.7", "spread": "23.30"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169.7", "spread": "10.25"}, {"groupId": "BG001", "value": "167.7", "spread": "10.35"}, {"groupId": "BG002", "value": "168.1", "spread": "10.35"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.6", "spread": "6.66"}, {"groupId": "BG001", "value": "32.2", "spread": "8.69"}, {"groupId": "BG002", "value": "32.2", "spread": "8.33"}]}]}]}, {"title": "Asthma Control Questionnaire (ACQ)", "description": "n=98, 396, 494 The ACQ score was measured using the ACQ-7. Six questions are-self assessments; the seventh item is the result of the patient's % predicted FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A score of 0 indicates good asthma control; higher scores indicate increasingly poorer asthma control.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.564", "spread": "0.6909"}, {"groupId": "BG001", "value": "2.558", "spread": "0.6992"}, {"groupId": "BG002", "value": "2.559", "spread": "0.6969"}]}]}]}, {"title": "Forced Expiratory Volume in 1 second (FEV1)", "description": "n=98, 396, 494", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.180", "spread": "0.6355"}, {"groupId": "BG001", "value": "2.101", "spread": "0.6950"}, {"groupId": "BG002", "value": "2.117", "spread": "0.6837"}]}]}]}, {"title": "Forced Vital Capacity (FVC)", "description": "n=98, 396, 494", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.215", "spread": "0.9076"}, {"groupId": "BG001", "value": "3.047", "spread": "0.9577"}, {"groupId": "BG002", "value": "3.081", "spread": "0.9494"}]}]}]}, {"title": "Forced Expiratory Flow at 25% to 75% of the Forced Vital Capacity (FEF25%-75%)", "description": "n=96, 393, 489", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters/second", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.553", "spread": "0.6791"}, {"groupId": "BG001", "value": "1.650", "spread": "0.9037"}, {"groupId": "BG002", "value": "1.631", "spread": "0.8645"}]}]}]}, {"title": "Percent Predicted Forced Expiratory Volume in 1 Second (% predicted FEV1)", "description": "n=98, 396, 494", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.5", "spread": "15.53"}, {"groupId": "BG001", "value": "66.8", "spread": "16.26"}, {"groupId": "BG002", "value": "66.7", "spread": "16.10"}]}]}]}, {"title": "Blood Eosinophil Counts", "description": "n=96, 397, 493", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "10^9 blood eosinophil/liter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.277", "spread": "0.2209"}, {"groupId": "BG001", "value": "0.281", "spread": "0.2448"}, {"groupId": "BG002", "value": "0.280", "spread": "0.2401"}]}]}]}, {"title": "Average Daily Use of Short-Acting Beta-Agonist Therapy (SABA) in Past 3 Days", "description": "n=98, 395, 493", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "puffs of SABA/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.0", "spread": "1.82"}, {"groupId": "BG001", "value": "1.9", "spread": "1.84"}, {"groupId": "BG002", "value": "1.9", "spread": "1.83"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry.\n\nData represent the slope estimate of change from baseline in FEV1 (measured in liters) at Week 16 versus baseline eosinophil count (measured in 10\\^9/liter) by treatment group.", "populationDescription": "Full analysis set (FAS) includes randomized patients treated with at least 1 dose of study drug, and had assessments in the timeframes. Pulmonary function tests were excluded if a limited subset of medications that could significantly confound interpretation were used within 7 days of scheduled visits.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "FEV1 liters/ eosinophils 10^9/liter", "timeFrame": "Baseline (Day 1), Week 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "344"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2778", "spread": "0.2379"}, {"groupId": "OG001", "value": "0.0229", "spread": "0.0944"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The primary analysis was the linear regression model with model effects including treatment (reslizumab or placebo), blood eosinophil count at baseline, and the interaction of treatment and eosinophil count. A significant treatment by baseline eosinophil interaction would indicate that treatment difference varies by the baseline eosinophil count.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2407", "pValueComment": "The interaction was tested at the significance level 0.10 using the FAS", "statisticalMethod": "Regression, Linear", "paramType": "slope difference", "paramValue": "0.3007", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2559", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.\n\nDuring study (Weeks 4, 8, 12 and 16) average value was calculated using a mixed effects model for repeated measures (MMRM) with treatment (reslizumab or placebo), blood eosinophil count at baseline, and the interaction of treatment and eosinophil count as a random effect.", "populationDescription": "Full analysis set (FAS) includes randomized patients treated with at least 1 dose of study drug, and contributed at least once to the analysis. Pulmonary function tests were excluded if a limited subset of medications that could significantly confound interpretation were used within 7 days of scheduled visits.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "390"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.175", "spread": "0.0377"}, {"groupId": "OG001", "value": "0.251", "spread": "0.0200"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The change from baseline over the 16 week treatment period was measured for the key secondary variables of:\n\n* Lung function as measured by FEV1\n* ACQ\n\nTesting of the key secondary variables was performed using the sequential testing procedure in the order as specified above at the alpha level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0697", "pValueComment": "Statistical significance level is 0.05.", "statisticalMethod": "Regression, Linear", "statisticalComment": "treatment, blood eosinophil count at baseline, and the interaction of treatment and eosinophil count as fixed effects.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.076", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.006", "ciUpperLimit": "0.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0417", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures", "description": "The ACQ score was measured using the ACQ-7. Six questions are-self assessments; the seventh item is the result of the patient's % predicted FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A score of 0 indicates good asthma control; higher scores indicate increasingly poorer asthma control. Negative change from baseline scores indicate improvement in asthma control.\n\nDuring study (Weeks 4, 8, 12 and 16) average value was calculated from mixed model repeated measures (MMRM) with treatment, visit, treatment by visit interaction, history of asthma exacerbation in the previous year, height, baseline value, and sex as fixed factors, and patient as a random effect.", "populationDescription": "Full analysis set of participants who contributed at least once to the analysis. ACQ were excluded from the FAS if they were obtained at scheduled visits which were preceded by usage within 7 days of a limited subset of medications that could significantly confound interpretation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "390"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.614", "spread": "0.0689"}, {"groupId": "OG001", "value": "-0.737", "spread": "0.0364"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The change from baseline over the 16 week treatment period was measured for the key secondary variables of:\n\n* Lung function as measured by FEV1\n* ACQ\n\nTesting of the key secondary variables was performed using the sequential testing procedure in the order as specified above at the alpha level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1072", "pValueComment": "significance level of 0.05", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "Fixed effects for treatment, hx of asthma exacerbation, sex, visit, and interaction of treatment and visit; covariates for height and baseline value", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.123", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.273", "ciUpperLimit": "0.027", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0762", "estimateComment": "Active - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopulation", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry.\n\nAs with the primary outcome, data represent the slope estimate of change from baseline in FEV1 (measured in liters) at Week 16 versus baseline eosinophil count (measured in 10\\^9/liter) by treatment group. However the FEV1 subpopulation includes participants with more impaired lung function (% predicted FEV1 \\<85% at baseline).", "populationDescription": "The FEV1 sub-population analysis set includes all participants in the FAS with % predicted FEV1 \\<85% at baseline. Pulmonary function tests were excluded if a limited subset of medications that could significantly confound interpretation were used within 7 days of scheduled visits.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "FEV1 liters/ eosinophils 10^9/liter", "timeFrame": "Baseline (Day 1), Week 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "346"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2944", "spread": "0.2443"}, {"groupId": "OG001", "value": "0.0271", "spread": "0.1019"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the volume of air expired in the first second of a forced expiration. Improvement in FEV1 is a measure in the reduction of bronchospasm, the reduction of airway inflammation, or both. FEV1 was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with FEV1 baseline values (one reslizumab participant was missing a valid baseline FEV1.) Number participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 4 (n= 96, 386)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.164", "spread": "0.0395"}, {"groupId": "OG001", "value": "0.224", "spread": "0.0208"}]}]}, {"title": "Week 8 (n= 93, 377)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.199", "spread": "0.0421"}, {"groupId": "OG001", "value": "0.249", "spread": "0.0220"}]}]}, {"title": "Week 12 (n= 90, 357)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.152", "spread": "0.0430"}, {"groupId": "OG001", "value": "0.277", "spread": "0.0226"}]}]}, {"title": "Week 16 (n=83, 344)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.187", "spread": "0.0446"}, {"groupId": "OG001", "value": "0.255", "spread": "0.0232"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16 and Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva. Positive change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with FEV1 baseline values (one reslizumab participant was missing a valid baseline FEV1.) Number participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 4 (n=96, 385)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "9.83"}, {"groupId": "OG001", "value": "6.7", "spread": "12.26"}]}]}, {"title": "Week 8 (n=93, 377)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.0", "spread": "9.9"}, {"groupId": "OG001", "value": "7.2", "spread": "13.41"}]}]}, {"title": "Week 12 (n=90, 357)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "spread": "10.36"}, {"groupId": "OG001", "value": "8.2", "spread": "13.23"}]}]}, {"title": "Week 16 (n=83, 344)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.5", "spread": "11.76"}, {"groupId": "OG001", "value": "7.8", "spread": "13.60"}]}]}, {"title": "Endpoint (n=96, 390)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.2", "spread": "11.76"}, {"groupId": "OG001", "value": "7.5", "spread": "13.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 4, 8, 12, and 16", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters. FV was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with FVC baseline values (one reslizumab participant was missing a valid baseline FVC.) Number participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 4 (n=96, 386)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.167", "spread": "0.0469"}, {"groupId": "OG001", "value": "0.235", "spread": "0.0247"}]}]}, {"title": "Week 8 (n=93, 377)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.179", "spread": "0.0474"}, {"groupId": "OG001", "value": "0.243", "spread": "0.0249"}]}]}, {"title": "Week 12 (n=90, 357)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.176", "spread": "0.0500"}, {"groupId": "OG001", "value": "0.284", "spread": "0.0263"}]}]}, {"title": "Week 16 (n=84, 345)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.234", "spread": "0.0506"}, {"groupId": "OG001", "value": "0.246", "spread": "0.0264"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Forced Expiratory Flow at 25% to 75% of the Forced Vital Capacity (FEF25%-75%) at Weeks 4, 8, 12, and 16", "description": "The FEF25%-75% is the forced expiratory flow at 25% to 75% of the forced vital capacity. FEF25%-75% was measured using forced expiratory air spirometry. Positive change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with FEF25%-75% baseline values. Number of participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters/second", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "391"}]}], "classes": [{"title": "Week 4 (n=93, 382)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.210", "spread": "0.0565"}, {"groupId": "OG001", "value": "0.184", "spread": "0.0295"}]}]}, {"title": "Week 8 (n=90, 374)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.270", "spread": "0.0609"}, {"groupId": "OG001", "value": "0.240", "spread": "0.0315"}]}]}, {"title": "Week 12 (n=87, 354)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.136", "spread": "0.0635"}, {"groupId": "OG001", "value": "0.256", "spread": "0.0329"}]}]}, {"title": "Week 16 (n=82, 342)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.179", "spread": "0.0875"}, {"groupId": "OG001", "value": "0.241", "spread": "0.0441"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Average Daily Use of Short-Acting Beta-Agonist Therapy (SABA) at Weeks 4, 8, 12, and 16", "description": "SABA are used for quick relief of asthma symptoms. The number of times SABA therapy was used was assessed using 3 day recall at scheduled visits. Participants were asked to recall whether SABAs were used within 3 days of the scheduled visit and, if so, how many puffs were used. Daily use was the average of those 3 days. Negative change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with SABA use baseline values. Number participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "puffs of SABA/day", "timeFrame": "Baseline (Day -2 to 1), Weeks 4, 8, 12, and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "392"}]}], "classes": [{"title": "Week 4 (n=96, 388)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.19"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.10"}]}]}, {"title": "Week 8 (n=94, 377)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.09"}]}]}, {"title": "Week 12 (n=89, 356)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "0.20"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.10"}]}]}, {"title": "Week 16 (n=84, 345)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Eosinophil Counts at Weeks 4, 8, 12, 16, Follow-up (Week 28) and Endpoint", "description": "Blood eosinophil counts were measured using a standard complete blood count with differential blood test at each scheduled visit. Follow-up was performed approximately 12 weeks after the 16 week treatment period. Endpoint is the last post-baseline assessment.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with blood eosinophil count baseline values. Number participants with assessments in the timeframes are listed with the time designation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9/liter", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12, 16, Follow-up (Week 28)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 4 (n=93, 385)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.010", "spread": "0.1917"}, {"groupId": "OG001", "value": "-0.226", "spread": "0.2297"}]}]}, {"title": "Week 8 (n=91, 372)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.036", "spread": "0.3104"}, {"groupId": "OG001", "value": "-0.239", "spread": "0.2389"}]}]}, {"title": "Week 12 (n=84, 353)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.027", "spread": "0.2082"}, {"groupId": "OG001", "value": "-0.240", "spread": "0.2418"}]}]}, {"title": "Week 16 (n=80, 346)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.021", "spread": "02466"}, {"groupId": "OG001", "value": "-0.239", "spread": "0.2462"}]}]}, {"title": "Follow-up (n=90, 364)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.035", "spread": "0.3369"}, {"groupId": "OG001", "value": "-0.159", "spread": "0.2301"}]}]}, {"title": "Endpoint (n=94, 392)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.036", "spread": "0.3306"}, {"groupId": "OG001", "value": "-0.169", "spread": "0.2294"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12 and 16", "description": "The ACQ score was measured using the ACQ-7. Six questions are self-assessments; the seventh item is the result of the patient's % predicted FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A score of 0 indicates good asthma control; higher scores indicate increasingly poorer asthma control. Negative change from baseline scores indicate improvement in asthma control.", "populationDescription": "Full analysis set. Number of participants analyzed represents # with ACQ baseline values. Number participants with assessments in the timeframes are listed with the time designation. ACQ were excluded if obtained at visits which were preceded by usage within 7 days of a limited subset of medications that could significantly alter interpretation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline (Day 1), Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 4 (n=96, 385)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.502", "spread": "0.0710"}, {"groupId": "OG001", "value": "-0.585", "spread": "0.0375"}]}]}, {"title": "Week 8 (n=93, 377)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.631", "spread": "0.0807"}, {"groupId": "OG001", "value": "-0.701", "spread": "0.0420"}]}]}, {"title": "Week 12 (n=90, 357)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.674", "spread": "0.0843"}, {"groupId": "OG001", "value": "-0.818", "spread": "0.0439"}]}]}, {"title": "Week 16 (n=83, 343)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.648", "spread": "0.0878"}, {"groupId": "OG001", "value": "-0.844", "spread": "0.0453"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "The safety analysis set includes all patients who took at least 1 dose of study drug, regardless of whether the patients were randomized.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 to Week 28", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "395"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "218"}]}]}, {"title": "Severe adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Treatment-related adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serious AEs other than death", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Treatment-related serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Withdrawn from study due to adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Withdrawn from study due to treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values during any of the lab tests conducted during the treatment period.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* Aspartate aminotransferase: \\>=3\\*upper limit of normal (ULN). Normal range is 10-43 U/L\n* Alanine aminotransferase: \\>=3\\*ULN. Normal range is 10-40 U/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*ULN. Normal range is 4-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* Creatinine phosphokinase: \\>5\\*ULN. Normal range is 24-207 U/L.\n* White blood cells: \\<=3.0 or \\>20 10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 L/L\n* Platelets: \\<=75 10\\^9/L\n* Absolute neutrophil count: \\<=1.0 10\\^9/L\n* Urinalysis: blood, glucose, ketones and total protein: \\>=2 unit increase from baseline", "populationDescription": "Safety analysis set with assessments", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4 to Week 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "393"}]}], "classes": [{"title": "Atleast 1 PCS abnormal serum blood chemistry value", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "26"}]}]}, {"title": "Blood urea nitrogen", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Uric acid", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Aspartate aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Alanine aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "GGT", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Total bilirubin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Creatinine phosphokinase", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "At least 1 PCS abnormal hematology value", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "White blood cells - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "White blood cells - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Hemoglobin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Hematocrit", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Platelets", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Absolute neutrophil count", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "At least 1 PCS abnormal urinalysis value", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "94"}]}]}, {"title": "Blood (hemoglobin)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "40"}]}]}, {"title": "Glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Ketones", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Total protein", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "43"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with potentially clinically significant (PCS) vital sign values during any of the treatment period exams.\n\nSignificance criteria\n\n* Heart rate - high: \\>100 and increase of \\>= 30 beats/minute (bpm)\n* Sitting systolic blood pressure - high: \\>160 and increase of \\>=30 mmHg\n* Sitting systolic blood pressure - low: \\<90 and decrease of \\>=30 mmHg\n* Sitting diastolic blood pressure - high: \\>100 and increase of \\>=12 mmHg\n* Sitting diastolic blood pressure - low: \\<50 and decrease of \\>=12 mmHg\n* Body temperature - high: \\>100.5\u00b0 Fahrenheit or 38.1\u00b0 Celsius and increase of \\>2\u00b0\n* Body temperature - low: \\<96.5\u00b0 Fahrenheit or \\<35.8\u00b0 Celsius", "populationDescription": "Safety analysis set of participants with assessments", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4 to Week 28", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "At least 1 PCS abnormality", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "43"}]}]}, {"title": "Heart rate", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Sitting systolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Sitting systolic blood pressure - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Sitting diastolic blood pressure - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Sitting diastolic blood pressure - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Body temperature - high", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Body temperature - low", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "25"}]}]}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Electrocardiogram (ECG) Abnormalities", "description": "Counts represent the number of participants with potentially clinically significant ECG abnormalities as assessed by the investigator.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 16 or endpoint", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "395"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Participants With a Positive Anti-Reslizumab Antibody Status During Study", "description": "Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion at screening, weeks 8 and 16 or early withdrawal. Serum samples from patients who were treated with reslizumab were analyzed for ADA by Teva (Teva Biopharmaceuticals USA, Rockville, MD) using a validated homogeneous solution-based bridging enzyme-linked immunosorbent assay (ELISA).\n\nEndpoint =week 16 or early withdrawal.\n\nCounts represent the total number of participants at each time point with a positive immunogenicity test, and not 'new' participants with a positive test. An overall status of positive includes participants who had a positive ADA at any time point.", "populationDescription": "Safety analysis set; antibody assessments reported for active treatment arm only.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Screening (Week -3), Weeks 8 and 16", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses."}, {"id": "OG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "395"}]}], "classes": [{"title": "Overall status - negative", "categories": [{"measurements": [{"groupId": "OG001", "value": "376"}]}]}, {"title": "Overall status - positive", "categories": [{"measurements": [{"groupId": "OG001", "value": "19"}]}]}, {"title": "Screening status - negative", "categories": [{"measurements": [{"groupId": "OG001", "value": "375"}]}]}, {"title": "Screening status - positive", "categories": [{"measurements": [{"groupId": "OG001", "value": "13"}]}]}, {"title": "Week 8 - negative", "categories": [{"measurements": [{"groupId": "OG001", "value": "346"}]}]}, {"title": "Week 8 - positive", "categories": [{"measurements": [{"groupId": "OG001", "value": "15"}]}]}, {"title": "Week 16 - negative", "categories": [{"measurements": [{"groupId": "OG001", "value": "328"}]}]}, {"title": "Week 16 - positive", "categories": [{"measurements": [{"groupId": "OG001", "value": "9"}]}]}, {"title": "Endpoint - negative", "categories": [{"measurements": [{"groupId": "OG001", "value": "375"}]}]}, {"title": "Endpoint - positive", "categories": [{"measurements": [{"groupId": "OG001", "value": "10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 to Week 28", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo intravenous injection every 4 weeks for a total of 4 doses.", "seriousNumAffected": 4, "seriousNumAtRisk": 97, "otherNumAffected": 41, "otherNumAtRisk": 97}, {"id": "EG001", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.", "seriousNumAffected": 16, "seriousNumAtRisk": 395, "otherNumAffected": 118, "otherNumAtRisk": 395}], "seriousEvents": [{"term": "Neurogenic bowel", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 395}]}, {"term": "Arthritis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 395}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 395}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Cerebral vasoconstriction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "VIIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 395}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 395}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 395}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 395}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 14, "numAffected": 14, "numAtRisk": 395}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 15, "numAffected": 13, "numAtRisk": 395}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 26, "numAffected": 22, "numAtRisk": 395}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 50, "numAffected": 42, "numAtRisk": 395}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 18, "numAtRisk": 97}, {"groupId": "EG001", "numEvents": 58, "numAffected": 48, "numAtRisk": 395}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000011657", "term": "Pulmonary Eosinophilia"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000017681", "term": "Hypereosinophilic Syndrome"}, {"id": "D000004802", "term": "Eosinophilia"}, {"id": "D000007960", "term": "Leukocyte Disorders"}, {"id": "D000006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "asFound": "Eosinophilic Asthma", "relevance": "HIGH"}, {"id": "M7961", "name": "Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M19901", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}, {"id": "M10963", "name": "Leukocyte Disorders", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "T2886", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000515492", "term": "Reslizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}, {"id": "M287460", "name": "Reslizumab", "asFound": "Diaphragmatic breathing exercises", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}